Najah Albadari
- Cancer Research top 10%
- Cancer, Hypoxia, and Metabolism 2
-
- Cancer-related Molecular Pathways 5
-
- Protein Degradation and Inhibitors 3
- Cancer therapeutics and mechanisms 3
- Ubiquitin and proteasome pathways 3
-
- Synthesis and biological activity 5
- Click Chemistry and Applications 2
-
- Neuroblastoma Research and Treatments 2
- Co-authors
- Wěi LiShanshan DengDuane D. MillerHao ChenDejian MaStephen W. WhiteJia ZhouWei Wang
- Journals
- Cancer Research (1 paper)Pharmacological Reviews (1 paper)Journal of Medicinal Chemistry (2 papers)
- Partner nations
- United StatesSaudi ArabiaChina
In The Last Decade
Najah Albadari
15 papers receiving 469 citations
Hit Papers
Peers
Comparison fields: 5 of 64
- Cancer Research 209
- Oncology 119
- Molecular Biology 269
- Organic Chemistry 78
- Toxicology 9
Countries citing papers authored by Najah Albadari
This map shows the geographic impact of Najah Albadari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Najah Albadari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Najah Albadari more than expected).
Fields of papers citing papers by Najah Albadari
This network shows the impact of papers produced by Najah Albadari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Najah Albadari. The network helps show where Najah Albadari may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Najah Albadari, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 1 | |
| 3 | 2025 | 1 | |
| 4 | MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Futurebreakdown → | 2024 | 56 |
| 5 | 2024 | 2 | |
| 6 | 2024 | 15 | |
| 7 | 2024 | 9 | |
| 8 | 2023 | 2 | |
| 9 | 2023 | 35 | |
| 10 | 2023 | 4 | |
| 11 | 2022 | 1 | |
| 12 | 2021 | 5 | |
| 13 | 2021 | 41 | |
| 14 | 2019 | 40 | |
| 15 | 2019 | 263 | |
| 16 | 2019 | 0 |
About Najah Albadari
Najah Albadari is a scholar working on Oncology, Toxicology and Organic Chemistry, having authored 16 papers that have together received 476 indexed citations. Recurring topics across this work include Synthesis and biological activity (5 papers), Cancer-related Molecular Pathways (5 papers), Protein Degradation and Inhibitors (3 papers), Cancer therapeutics and mechanisms (3 papers), Ubiquitin and proteasome pathways (3 papers), Click Chemistry and Applications (2 papers), Cancer, Hypoxia, and Metabolism (2 papers) and Neuroblastoma Research and Treatments (2 papers). The work is most often cited by research in Cancer Research (209 citations), Oncology (119 citations) and Molecular Biology (269 citations). Najah Albadari has collaborated with scholars based in United States, Saudi Arabia and China. Frequent co-authors include Wěi Li, Shanshan Deng, Duane D. Miller, Hao Chen, Dejian Ma, Stephen W. White, Jia Zhou, Wei Wang, Ruiwen Zhang and Wa Xian. Their work appears in journals such as Cancer Research, Pharmacological Reviews and Journal of Medicinal Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.